Multimedia

Videos

What is a Phase 3 Clinical Trial for a Vaccine Candidate?

Through the ACTIV program, Â鶹´«Ã½ is working with many partners to develop safe and effective vaccines for COVID-19. Learn how candidate vaccines are tested through the different phases of clinical trials.

Monoclonal Antibodies

Learn about monoclonal antibodies, which are being tested in NIH clinical trials as a potential treatment for COVID-19. Learn more about these trials

Graphics

NIH and Moderna launched a Phase 3 clinical trial in July 2020 to study COVID-19 vaccine candidate mRNA-1273.

NIH and Moderna launched a Phase 3 clinical trial in July 2020 to study COVID-19 vaccine candidate mRNA-1273. Learn more

In August of 2020 NIH announced ACTIV-2, a Phase 2/3 clinical trial to study the use of monoclonal antibodies as a treatment for COVID-19 in an outpatient setting for people with mild to moderate COVID-19.

In August 2020 NIH announced ACTIV-2, a Phase 2/3 clinical trial to study the use of monoclonal antibodies as a treatment for COVID-19 in an outpatient setting for people with mild to moderate COVID-19.

In August of 2020 NIH announced a Phase 3 clinical trial to study the use of monoclonal antibodies as a treatment for hospitalized COVID-19 patients as part of ACTIV-3.

In August 2020 NIH announced a Phase 3 clinical trial to study the use of monoclonal antibodies as a treatment for hospitalized COVID-19 patients as part of ACTIV-3. Learn more

Photos

Fauci, Hepburn, and Collins in Hallway

From left to right: Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, Dr. Matt Hepburn, Vaccine Lead for Operation Warp Speed, and Â鶹´«Ã½ Director Dr. Francis Collins  ar Â鶹´«Ã½ Building 1 on July 27, 2020, after a press briefing on the Phase 3 trial launch of the investigational vaccine mRNA-1273 for COVID-19. (NIH News Release) Photo credit: NIH

This page last reviewed on August 25, 2020